In this issue of the Journal of Dermatological Treatment, Thomsen et al. update us on
biologics in the treatment of inflammatory skin diseases. The advances in safety and efficacy …

All available antipsoriatic therapies are of symptomatic character. Treatments established so
far are limited in their use due to side effects or lack of efficacy resulting in poor quality of life …

Over the past 20years, innovations in psoriasis treatment included biologics (anti-TNF, anti-
IL-17 and anti-IL23), several small molecule oral agents (apremilast and deucravacitinib) …

Psoriasis is a chronic, immune-mediated inflammatory disorder affecting 2---3% of general
population, being both physically and emotionally debilitating. 1, 2 Due to the rapid …

Most dermatologists are still involved with the management of patients with psoriasis.
Despite its ubiquitous presence in outpatient clinics and monopoly of dwindling inpatient …

During the last 30 years, the tremendous progress in our knowledge of the pathogenesis of
psoriasis has led to the development of new agents, the so-called biologics, that have …

The introduction of biologics has not only broadened the therapeutic armamentarium for
psoriasis but also stimulated discussion about the treatment of this common skin condition …

Biologics have greatly improved the treatment of moderate-to-severe plaque psoriasis, as
most patients are now able to achieve an initial improvement of 75% in the Psoriasis Area …

A number of new systemic agents, collectively termed as 'biologicals,'are made available for
the treatment of psoriasis. We can display cautious optimism as to the role of these new …

New treatments have revolutionized the care of psoriasis in recent years, enabling patients
and clinicians to set aggressive goals for disease clearance. This article reviews the …